États-Unis · Plateformes & données · MarketBeat

What Journey Medical (DERM) Said on Its Q3 Earnings Call

Publié par MarketBeat · États-Unis il y a 22 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Journey Medical (NASDAQ:DERM) reported higher third-quarter revenue and a narrower net loss as sales of its rosacea treatment Emrosi grew, while executives said broader insurance coverage could support the product’s pricing and revenue in 2027. The company reported total revenue of $19 million for

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

What Journey Medical (DERM) Said on Its Q3 Earnings Call

Résumé détaillé

À lire aussi

GAAP EPS of -$0.08 beats by $0.03, revenue of $2.81M misses by $0.19M

Who can replace Jensen Huang as Nvidia CEO? These four names are buzzing in AI circles.

In a policy switch, the Fed says its October 2027 meeting will not see a vote on interest rates

IRS 2027 retirement limits: 401(k) caps jump while IRA limits freeze again

Standard Lithium Files September 2026 Interim Financial Statements

The bond market now has an even bigger fear than the AI fallout

What Journey Medical (DERM) Said on Its Q3 Earnings Call

Résumé détaillé

Partager

À lire aussi

GAAP EPS of -$0.08 beats by $0.03, revenue of $2.81M misses by $0.19M

Who can replace Jensen Huang as Nvidia CEO? These four names are buzzing in AI circles.

In a policy switch, the Fed says its October 2027 meeting will not see a vote on interest rates

IRS 2027 retirement limits: 401(k) caps jump while IRA limits freeze again

Standard Lithium Files September 2026 Interim Financial Statements

The bond market now has an even bigger fear than the AI fallout